How Should Administrators Deal With School Fraternities and Sororities?

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/67940/2/10.1177_019263654903316303.pd

How May We Make the Recording and Reporting of Pupil Achievement more Meaningful?

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/68105/2/10.1177_019263655303719436.pd

Serotyping for homotransplantation V. Evaluation of a matching scheme

An attempt was made to determine whether 36 long-term kidney homograft recipients and their donors were compatible for 7 major leukocyte groups. It was found that 21 of these recipients were surviving 2 to 3 years in spite of incompatibility for 1 or 2 major leukocyte antigens. Survival of mismatched grafts does not itself indicate that the antigens being measured are not transplantation antigens, for it was shown that the 15 recipients with no groups of mismatch were clinically superior to those with group incompatibilities. Moreover, histopathologic scores given to biopsy specimens taken 2 to 3 years after transplantation were significantly correlated with the number of group mismatches. Because the leukocyte groups were determined by cytotoxicity reactions of peripheral blood lymphocytes, the results may have been influenced considerably by chimerism in chronically dialyzed uremic patients or change in lymphocyte antigenicity or susceptibility to lysis upon prolonged immunosuppressive treatment. Although the possibility of these complications could not be ruled out in all instances, it was shown that 52 dialyzed uremic patients and 49 patients who had been treated with immunosuppression for over 1 year did not possess more or less antigens than a random population of normal individuals. It is concluded that: (1) the major leukocyte antigens are histocompatibility antigens, and (2) since survival can be attained at times despite mismatches for these groups, the antigens are of intermediate strength and kidney homograft rejection may occur if excessive numbers of antigens are incompatible or if particular combinations of antigens are mismatched. © 1966 by The Williams and Wilkins Co

Biology and parasitism rates of Pteromalus nr. myopitae (Hymenoptera: Pteromalidae), a newly discovered parasitoid of olive fruit fly Bactrocera oleae (Diptera: Tephritidae) in coastal California

An undescribed wasp, Pteromalus nr. myopitae (Hymenoptera: Pteromalidae) opportunistically parasitizes the olive fruit fly Bactrocera oleae (Rossi) (Diptera: Tephritidae), an introduced pest of olives in California. The native or typical host of P. nr. myopitae is unknown. We demonstrate that P. nr. myopitae is a solitary, ectoparasitic, idiobiont parasitoid of the third instar host inside fruit, and pupation occurs in the host tunnel. Reproduction of P. nr. myopitae on B. oleae in olives in the laboratory and in field cages generally failed. Host-feeding was not observed, and adults fed honey and water lived longer than those provided with water alone. Parasitism in non-commercial olives in the moderate coastal climate of San Luis Obispo occurred primarily from August to October, and was absent from a nearby location with more extreme climate and a low population of B. oleae. Greater parasitoid numbers were associated with greater host densities, and proportion of hosts parasitized was generally higher at lower host densities during 2 years of the study. The geographic range of the parasitoid extends along the coast from San Francisco Bay to Ensenada, Baja California, Mexico, and also inland in the Sacramento Valley, with one record in the San Joaquin Valley. The potential of the parasitoid as a biological control agent of B. oleae is probably low, however, the extent of its interference with other parasitoids being considered for release in California is unknown and warrants further study

Statins in the Treatment of Chronic Heart Failure: A Systematic Review

BACKGROUND: The efficacy of statin therapy in patients with established chronic heart failure (CHF) is a subject of much debate. METHODS AND FINDINGS: We conducted three systematic literature searches to assess the evidence supporting the prescription of statins in CHF. First, we investigated the participation of CHF patients in randomized placebo-controlled clinical trials designed to evaluate the efficacy of statins in reducing major cardiovascular events and mortality. Second, we assessed the association between serum cholesterol and outcome in CHF. Finally, we evaluated the ability of statin treatment to modify surrogate endpoint parameters in CHF. Using validated search strategies, we systematically searched PubMed for our three queries. In addition, we searched the reference lists from eligible studies, used the “see related articles” feature for key publications in PubMed, consulted the Cochrane Library, and searched the ISI Web of Knowledge for papers citing key publications. Search 1 resulted in the retrieval of 47 placebo-controlled clinical statin trials involving more than 100,000 patients. CHF patients had, however, been systematically excluded from these trials. Search 2 resulted in the retrieval of eight studies assessing the relationship between cholesterol levels and outcome in CHF patients. Lower serum cholesterol was consistently associated with increased mortality. Search 3 resulted in the retrieval of 18 studies on the efficacy of statin treatment in CHF. On the whole, these studies reported favorable outcomes for almost all surrogate endpoints. CONCLUSIONS: Since CHF patients have been systematically excluded from randomized, controlled clinical cholesterol-lowering trials, the effect of statin therapy in these patients remains to be established. Currently, two large, randomized, placebo-controlled statin trials are under way to evaluate the efficacy of statin treatment in terms of reducing clinical endpoints in CHF patients in particular

Dealing with School Fraternities and Sororities

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/67603/2/10.1177_019263654803215303.pd